by Raynovich Rod | Aug 31, 2016 | Biopharmaceuticals
Update-2… 945 am EDT…Biotechs Hold Support IBB up 1.55% to $285 holding support at $280; XBI up 2.99% to $61.95 holding support at $60. Update-1…More Fallout from Mylan (MYL) EpiPen Drug Pricing MYL stock was down over 4% today on news that the...
by Raynovich Rod | Aug 12, 2016 | Biopharmaceuticals
Large Cap Biopharmaceutical Valuation Models Can Biotech Growth Re-accelerate in Q4? We reviewed large cap biotech stocks on July 3 just after the BREXIT bottom but prior to Q2 earnings and on May 8 after Q1 earnings. Here is data that offer comparisons of the core...
by Raynovich Rod | Aug 10, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update August 15 : Biotech Leads But Healthcare Sector Lags IBB up 0.92% to $295, XBI up 1.33% to $63.35, XLV up 0.17% to $74.91 The tape was pretty decent despite a quiet day with ALXN up 1.97%, AMGN up 1.49% and CELG up 1.08%. Mid-caps also found bids: ALKS up...
by Raynovich Rod | Jun 3, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
BIO International Conference-Trends in the Biotechnology Industry We will be attending BIO International Convention in San Francisco next week and will provide news updates on relevant topics such as Personalized Medicine, biopharma drug policy and pricing, and next...
by Raynovich Rod | Jun 2, 2016 | Clinical Diagnostics and Tools
Update -1 NH closes at $18.59 up 32.79% on volume of 3.3M shares. High was $21 low was $16.11. Market cap is $2.1B. Focus of the Company is personalized healthcare utilizing a unique software platform (NantOS) applying molecular diagnostics and genomics on patient...
by Raynovich Rod | Apr 28, 2016 | Biopharmaceuticals
Immuno-Oncology: Sweet Spot in a Biotech Bear Market We will continue to track large cap biopharma Q1 earnings looking for value+growth ideas. The financial metrics will be tracked as we did in our original post, “Large Cap Winners and Losers” on February...
by Raynovich Rod | Feb 16, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Rayno Large Cap Biopharmaceuticals…Part 2…A Stock pickers Market Time to Rebuild Your Portfolio: ABBV, BMY, GILD Below we have summarized selective metrics for large cap biopharmaceutical companies. We began the process of revising and rebalancing our...
by Raynovich Rod | Jan 12, 2016 | 2023-24 Life Science Portfolios
J.P.Morgan Conference: Relief Rally in Life Science Stocks After Rough Start to 2016 Green screen day with improved macro and healthcare sector leading Who knew biotech stocks traded with energy? Over the next few days we will review themes and companies from...
by Raynovich Rod | Dec 16, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update after close 12/16…IBB up 2.25%, XBI up 4.45% Rayno Life Science Big Movers Rayno Biopharma ABBV up 2.2%,ALKS up 8.12%, BIIB up 3.52%, ARRY up 20.63 %, CRIS up 6.27%, FCSC up 5%, GERN up 4.42%,RXDX up 2.92% and SGEN up 4.93%. Rayno Dx and Tools ABAX up...
by Raynovich Rod | Nov 25, 2015 | Biopharmaceuticals
Slow But Steady Biotech Rally RNA Therapeutics-Duchenne Muscular Dystrophy (DMD) Despite some overhanging concerns about drug pricing and major setbacks from clinical trials like Clovis Oncology (CLVS) and BioMarin Pharmaceutical (BMRN) the sector looks like it wants...